1. Scrip
  2. >>Business
  3. >>Deals

J&J Gets Into The Anti-TSLP Game With Proteologix Buyout

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The privately held biotech will bring J&J a pair of bispecific antibodies expected to target multiple pathologic pathways in atopic dermatitis and asthma.

Deal (Sergey Nivens/Shutterstock.com)
J&J makes its second biopharma acquisition of the year with Proteologix deal

Interest in the anti-TSLP space continued on 16 May with Johnson & Johnson agreeing to pay $850m up front to acquire privately held Proteologix Inc. and its pipeline of bispecific antibodies, led by a Phase I-ready candidate that targets both IL-13 and the thymic stromal lymphopoietin (TSLP) pathway.

Key Takeaways

  • J&J will pay $850m to acquire Proteologix and its pipeline of bispecific antibodies for dermatologic and respiratory indications.

J&J said it intends to develop that lead candidate – PTX128 – in both moderate-to-severe atopic dermatitis and moderate-to-severe asthma....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.